For example, Nguyen et al. indicated that the treatment of peripheral blood mononuclear cells (PBMCs) from RA patients with adalimumab, an anti-TNF antibody, induced the IL-2/STAT5 signaling pathway and in vitro expansion of regulatory T cells (Treg), resulting in the decreased functionality and number of Th17 cells [7, 8]. Here, TNF is linked to rheumatoid arthritis.